COVID-19: patients with stroke or risk of stroke

Hans-Christoph Diener1*, Peter Berlit2, and Jaime Masjuan3

1Institute of Medical Informatics, Biometry and Epidemiology (IMIBE) Faculty of Medicine, University Duisburg-Essen, Hufelandstraße 55, Essen, 45147, Germany
2German Society of Neurology, Reinhardtstr. 27 C, Berlin, 10117, Germany and
3Departamento de Medicina, Universidad de Alcalá, Red INVICTUS, Servicio de Neurología, Hospital Universitario Ramón y Cajal, IRYCIS, Madrid, Spain

KEYWORDS
COVID-19; Stroke; Pathophysiology; Intracerebral haemorrhage

In the context of COVID-19 infection, 0.5–2% of affected patients will suffer a stroke. The strokes are usually severe with an unfavourable prognosis. Most patients suffer from occlusion of the large brain-supplying arteries caused by the COVID-19 induced coagulation disorders. In the context of COVID-19 infection, there has been a dramatic temporary decrease in the number of stroke patients treated in stroke units.

Introduction

In August 2020, COVID-19 had infected 17 million people worldwide, resulting in more than 700 000 deaths. The main manifestation of the viral disease is an atypical pneumonia. In addition, many other organ systems are affected, with 0.5–2% of patients suffering a stroke.1

Impact of the COVID-19 pandemic on stroke care

Shortly after the beginning of the pandemic, it was reported in many European countries as well as in the USA and Canada that the number of patients admitted to stroke units was declining dramatically.2,3 The decrease was mainly in patients with transient ischaemic attack (TIA) and a mild stroke. Both the patients themselves and the doctors treating them often refused a referral to a hospital for fear of infection. However, patients with severe strokes continued to be admitted. A further problem was that in many hospitals, beds from the stroke unit were converted into ventilation beds for the treatment of COVID-19 patients. The decrease in the number of patients screened for thrombectomy in the USA with the RAPID software decreased by more than 50% in April 2020 in the USA.4 In the meantime, the situation has returned to normal and all stroke units in most countries are back in normal operation. In the current situation, it remains crucial that the acute treatment of severe stroke with thrombectomy is performed under appropriate protective measures due to the proximity to the patient and the danger of aerosol spread.

Impact of the COVID-19 pandemic on stroke research

During the COVID-19 pandemic, most of the ongoing studies on acute stroke therapy and secondary prevention had to be interrupted until the end of June 2020.5 However, this hardly affected any registry studies. Most of the studies have since resumed recruitment. Patient follow-up is performed via telemedicine or phone calls.

Pathophysiology

COVID-19 infection leads to disorders of the coagulation system with an increased risk of thrombosis and embolism.6 This could explain why most strokes that occur during COVID-19 infection are caused by occlusions of the large brain-supplying arteries.7
Lacunar infarctions occurred in a minority of patients. In individual cases, it is difficult to differentiate, whether the COVID-19 infection was the cause of the stroke or whether the stroke would have occurred independently of the infection.

**Stroke as a complication of COVID-19 infection**

Several studies have shown that the incidence of stroke in patients with COVID-19 infection ranges from 0.9% and 2.7%. COVID-19 infection primarily leads to severe interstitial pneumonia. Some patients also develop neurological manifestations, including stroke. Most patients are severely affected, with a mortality rate of about 40%. Regardless of the presence of infection, patients who arrive at the hospital within the appropriate time window were treated with systemic thrombolysis or mechanical thrombectomy.

In 86 severely ill COVID-19 patients from China, 6 had a recent ischaemic stroke and 1 patient had a cerebral haemorrhage. A significantly higher prevalence of antiphospholipid antibodies was described in the seven brain-infarct patients (83.3 vs. 26.9%, \( P < 0.05 \)). In a cohort study including 187 patients at Montefiore Medical Center in the Bronx, New York, an increased incidence of Lupus Anticoagulans (LA) positivity was found in patients with COVID-19 after adjusting for C-reactive protein (CRP) levels. In addition, of the 30 patients who were LA positive, 19 had documented thrombosis (arterial and venous) including 2 strokes, an event rate of 63%, as compared with a rate for LA-negative patients of 34% (\( P = 0.03 \)).

A multicentre international registry (the Global Covid-19 Stroke Registry) performed a 1:1 propensity score matching analyses comparing stroke severity and outcomes in 174 patients with acute ischaemic stroke and COVID-19 with 336 non-COVID-19 ischaemic strokes registered in the Lausanne Registry. The median National Institute of Health Stroke Scale was higher in patients with COVID-19 (10) vs. 6 (IQR 3-14), \( P = 0.03 \); [odds ratio 1.69; 95% confidence interval (CI) 1.08-2.65]. Patients with COVID-19 had a higher risk for sever disability [median mRS 4 (IQR 2-6) vs. 2 (inter quantile range (IQR) 1-4), \( P < 0.001 \)] and death (odds ratio 4.3, 95% CI 2.22-8.30) compared with patients without COVID-19.

A working group from Spain presented its results on strokes in the context of the COVID-19 pandemic. In March and April 2020, 1683 patients with COVID-19 infection were admitted to the hospital, 23 (1.4%) of whom had a stroke. Seventeen patients had cerebral ischaemia (73.9%), two of whom had arterial dissection. Five patients had an intracerebral haemorrhage (21.7%) and one patient had leuкоencephalopathy of the posterior reversible constrictive syndrome. Patients with haemorrhage included subarachnoid haemorrhage, parieto-occipital leuкоencephalopathy, multiple microbleeds, and focal haematomas. The prognosis was unfavourable in 74% of the stroke patients.

A working group from New York conducted a retrospective case-control study in six hospitals. Among all patients admitted to the hospitals between 16 March and 5 April 2020, 126 patients presented with acute ischaemic stroke. The stroke patients were matched with patients without stroke in a ratio of 1:2 with regards to age, sex, and vascular risk factors. This matching resulted in 41 patients with stroke and 82 controls. The mean age of the cases and controls was 65.5 years and 68.8 years. Of the patients with acute ischaemic stroke, 46.3% had COVID-19 infection, compared to 18.3% of the controls (\( P < 0.001 \)). After multivariate adjustment for age, sex and risk factors, patients with COVID-19 infection had a significant association with acute ischaemic stroke compared to controls (odds ratio 3.9, 95% CI 1.7-8.9; \( P < 0.001 \)).

A study group from the National Hospital, Queen Square, UK, established a weekly multidisciplinary COVID-19 conference and collected detailed clinical and laboratory data from 43 patients with polymerase chain reaction (PCR)-confirmed or WHO criteria probable COVID-19 infection. Ischaemic strokes were found in eight patients, four of them with confirmed thrombocytopenia, one of whom died.

In a retrospective multicentre study from Italy, the imaging findings of 108 COVID-19 patients with neurological symptoms were analysed. 107 (99%) received a native CT, 17 (16%) a CT angiography (CTA) and 20 (18%) an MRI. Acute ischaemic infarctions were found in 34 (31%) patients [30 (28%) on CT and 4 (20%) on MRI]. There were 19 (18%) territorial infarctions (15 middle cerebral artery (MCA), 2 posterior cerebral artery (PCA), and 2 anterior cerebral artery (ACA), 11 (10%) were lacunar, 3 (3%) cardioembolic, and 1 (1%) patient showed a pattern of hypoxic-ischaemic encephalopathy. Three of the 6 (6%) intracranial bleedings were subarachnoid haemorrhages.

**Anticoagulation**

COVID-19 infection leads to coagulation disorders in many patients, with the development of thrombosis and embolism in both the arterial and venous circulation areas. This explains why COVID-19 patients are more prone to ischaemic strokes, systemic embolisms, deep vein thrombosis, and pulmonary embolism. If a causal relationship exists, anticoagulation should reduce the risk of these thrombo-embolic events and lead to a better prognosis. A retrospective analysis from five hospitals in New York investigated the association of anticoagulation with mortality in patients with COVID-19. Patients were enrolled between 1 March and 30 April 2020. The primary endpoint of the study was hospital mortality. Secondary endpoints were the need for intubation and serious bleeding complications.

A total of 4089 patients met the inclusion criteria for the registry. The median age was 65 years and 44% of the patients were female. A total of 900 patients received therapeutic anticoagulation, 1959 prophylactic anticoagulation, and 1530 patients did not receive anticoagulation. In total, 1073 patients (20.4%) died during the study.

- Of the patients who did not receive anticoagulation, 931 (60.8%) were discharged alive, 392 (25.6%) died in hospital, and 207 (13.5%) were still in the hospital.
• Of the patients who received prophylactic anticoagulation, 1472 (75.1%) were discharged alive, 424 (21.6%) died in hospital, and 63 (3.2%) were still hospitalized.

• In the group of patients receiving therapeutic anticoagulation, 89 patients (54.3%) were discharged alive, 257 (28.6%) died in hospital, and 154 (17.1%) were still in hospital.

Therapeutic anticoagulation resulted in a 47% reduction in in-hospital mortality (HR 0.53, 95% CI 0.45-0.6; P < 0.001). Patients who received prophylactic anticoagulation had a 50% reduction in mortality (HR 0.50, 95% CI interval 0.45-0.57; P < 0.01) compared to patients who did not receive anticoagulation. The rate of severe bleeding was 3% with therapeutic anticoagulation, 1.7% with prophylactic anticoagulation, and 1.9% in the patient without anticoagulation. Only very few patients received unfractionated heparin.

In conclusion, in hospitalized patients with COVID-19 infection, both prophylactic and therapeutic anticoagulation are able to improve hospital mortality and prognosis.

Future directions

The exact pathophysiological relationships between COVID-19 and stroke are not yet understood. It is also unknown whether treatment of COVID-19 patients with, for example, Remdesivir, reduces or anticoagulants22 the risk of stroke.

Funding

This paper was published as part of a supplement supported by an educational grant from Abbott.

Conflict of interest: none declared.

References

1. Argenziano MG, Bruce SL, Slater CL, Tiao JR, Baldwin MR, Barr RG, Chang BP, Chau KH, Choi JJ, Gavin H, Goyal P, Mills AM, Patel AA, Romney MS, Safford MM, Schluger NW, Sengupta S, Sipesczczyk ME, Zucker JE, Asadourian PA, Bell FM, Boyd R, Cohen MF, Colquhoun MI, Colville LA, de Jonge JH, Dershowitz LB, Dey SA, Eisterman KA, Girvin ZP, Goni DT, Harb AA, Herzkil N, Householder S, Kruuse C, Lamprecht B, D’Onillon CR, Otero F, García-Pastor A, Goni DT, Harb AA, Herzik N, Householder S, Karaaslan LE, Lee H, Lieberman E, Lui A, Liu Y, Shou HY, Sisti AC, Snow ZE, Sperring CP, Xiong Y, Zhou HW, Natarajan K, Hриpcas G, Chen R. Characterization and clinical course of 1000 patients with coronavirus disease 2019 in New York: retrospective case series. BMJ 2020;369:m1996.

2. Markus HS, Brainin M. COVID-19 and stroke - a global World Stroke Organization perspective. Int J Stroke 2020;15:361-364.

3. Butt JH, Fosbol EL, Østergaard L, Yafasova A, Andersson C, Schou M, Gerdts TA, Philips KM, Kruuse C, Gislason GH, Torp-Pedersen C, Køber L. The impact of coronavirus disease 2019 (COVID-19) on first-time acute stroke and transient ischemic attack admission rates and prognosis in Denmark: a nationwide cohort study. Circulation 2020;142:1227-1229.

4. Kangasapra AG, Goyal MS, Hamilton S, Albers GW. Collateral effect of COVID-19 on stroke evaluation in the United States. N Eng J Med 2020;383:400-401.

5. Broderick JP, Elm JJ, Janis LS, Zhao W, Moy CS, Dillon CR, Chinowitz MI, Sacco RL, Cramer SC, Wolf SL, Johnston KC, Saver JL, Marshall RS, Brown D, Wintermark M, Elkkind MSV, Kanel H, Tischwell DL, Longstreth WT, Chervin RD, Adeoye OM, Barreto AD, Grotta JC, Ramey SL, Lo WD, Feng W, Schlaga G, Sheth KN, Selim M, Naidech AM, Lansberg MG, Lazar RM, Albers GW, Griffin JS, Srirane LP, Frasure J, Wright CB, Khatiri P: on behalf of the NIH StrokeNet Investigators. National Institutes of Health StrokeNet during the time of COVID-19 and beyond. Stroke 2020;51:2526–2536.

6. Wang J, Sagarun AM, An J, Ning Y, Yan Y, Li G. Dysfunctional coagulation in COVID-19: from cell to bedside. Adv Ther 2020;37:3033-3039.

7. Hernández-Fernández F, Valencia HS, Barbeila-Aponte RA, Collado-Jiménez R, Ayoo-Martín O, Barrera C, Molina-Nuevo JD, García-García JC, Lozano-Setién E, Alcañiz-Rodríguez C, Martínez-Martín A, Sánchez-López A, Segura T. Cerebrovascular disease in patients with COVID-19: neuroimaging, histological and clinical description. Brain 2020;143:3089-3103.

8. Tan YK, Goh C, Leow AST, Tambyah PA, Ang A, Yap ES, Tu TM, Sharma VK, Yeo LLL, Chan BPL, Tan BYQ. COVID-19 and ischemic stroke: a systematic review and meta-summary of the literature. J Thromb Thrombolysis 2020;50:587-595.

9. Paterson RW, Brown RL, Benjamin L, Nortley R, Wiesthoff S, Bharucha T, Jayaseelan DL, Kumar G, Raftopoulos RE, Zambraun L, Vivekanandan V, Kho A, Geraldes R, Chintphalli P, Boyd E, Tuzlali H, Price G, Christofi G, Morrow J, McNamara P, Mcloughlin B, Lim ST, Mehta PR, Lievee V, Reddie S, Wong Y, Trip SA, Foukles AJM, Hotton G, Miller TD, Everett AD, Carswell C, Davies NWS, Carswell C, Davies NWS, Yoong M, Attwell D, Sreedharan J, Silber E, Schott JM, Chandrathvecha A, Perry RJ, Simister R, Checkley A, Llongyer N, Farmer SF, Carletti F, Houlihan C, Thom M, Lunn MP, Spillane J, Howard R, Vincent A, Werring DJ, Hoskote C, Jager HR, Manji H, Zandi MS; UCL Queen Square National Hospital for Neurology and Neurosurgery COVID-19 Study Group. The emerging spectrum of COVID-19 in neurology: clinical, radiological and laboratory findings. Brain 2020;143:1304-1320.

10. Zhang L, Sun W, Wang Y, Wang X, Liu Y, Zhao S, Long D, Chen L, Yu L. Clinical course and mortality of stroke patients with coronavirus disease 2019 in Wuhan, China. Stroke 2020;51:2674-2682.

11. Fan S, Xiao M, Han F, Xia P, Bai X, Chen H, Zhang H, Ding X, Zhao H, Zhao J, Sun X, Jiang W, Wang C, Cao W, Guo F, Tian R, Gao P, Wu W, Ma J, Wu D, Liu Z, Zhou X, Wang J, Guan T, Qin Y, Li T, Xu Y, Zhang D, Chen Y, Xie J, Li Y, Yan X, Zhu Y, Peng B, Cui L, Liao S, Zhang G, Guan S, Neurological manifestations in critically ill patients with COVID-19: a retrospective study. Front Neurol 2020;11:806.

12. Reyes Gil M, Barouqa M, Szmysłowski J, Gonzalez-Lugo JD, Rahman S, Billiet HH. Assessment of lupus anticoagulant positivity in patients with coronavirus disease 2019 (COVID-19). JAMA Netw Open 2020;3:e2017539.

13. Ntaios G, Michel P, Georgiopolous P, Guo Y, Li W, Xiong J, Cuadra I, Ometros Y, González-Ortega G, Fuentes B, Alonso de Lechína M, Diez-Tecedor E, Madrorna-S, Masjuan J, DeFelipe A, Turc G, Gonçalves B, Domigo V, Dan G-A, Vezzuetu R, Christensen H, Christensen LM, Meden P, Hajdarevic L, Rodríguez-López A, Díaz-Otero F, García-Pastor A, Gil-Nuñez A, Mañas I, Estrambo D, Werring DJ, Chandrathvecha A, Benjamin L, Simister R, Perry R, Beyrouti R, Jabbour P, SwiIid A, Tjoumakaris S, Cuadrado-Godia E, Campello AR, Roquer J, Moreira T, Mazza MV, Bandini F, Matz K, Iversen HK, González-Duarte A, Tiu C, Ferrari J, Vosko MR, Salzer HJF, Lamprecht B, Dünser MW, Cereda CW, Quintero ABC, Körnerkopf E, Soriano-Navarro E, Soto-Ramírez LE, Castejón-Méndez P, Bayan-Sanzores D, Araú A, Cama-Nélvda V, Kristoffersen ES, Tsaímen T, Stribian D, Putaal A, Lip GYH. Characteristics and outcomes in patients with COVID-19 and acute ischemic stroke: the global COVID-19 stroke registry. Stroke 2020;51:e254-e258.

14. Yagli S, Iskha K, Torres J, Mac Grory B, Raz E, Humbert K, Yaghi S, Ishida K, Torres J, Mac Grory B, Raz E, Humbert K, Carama R, Gómez-Caraballo I, Rodríguez-Sánchez E, Tisserand A, Delgado-Díez P, Arvind V, Bose S, Charney AW, Chen MD, Sandoval-J, Revill R, Amin, D, Sreedharan J, Silber E, Schott JM, Chandratheva A, Perry RJ, Simister R, Checkley A, Llongyer N, Farmer SF, Carletti F, Houlihan C, Thom M, Lunn MP, Spillane J, Howard R, Vincent A, Werring DJ, Hoskote C, Jager HR, Manji H, Zandi MS; UCL Queen Square National Hospital for Neurology and Neurosurgery COVID-19 Study Group. The emerging spectrum of COVID-19 in neurology: clinical, radiological and laboratory findings. Brain 2020;143:1304-1320.

15. Mahammedi A, Saba L, Vagai A, Leali M, Rossi A, Gaskill M, Sengupta S, Zhang B, Carriero A, Bachir S, Crivelli P, Pasche A, Premi E, Padovan A, Gasparotti R. Imaging in neurological disease of hospitalized COVID-19 patients: an Italian multicenter Retrospective Observational Study. Radiology 2020;297:E270-E273.

16. Nadkarni GN, Lala A, Bagiella E, Chang HL, Moreno P, Pujadas E, Arvind V, Bose S, Charney AW, Chen MD, Cordon-Carlo C, Dunn AS,
Farkouh ME, Glicksberg B, Kia A, Kohli-Seth R, Levin MA, Timsina P, Zhao S, Fayad ZA, Fuster V. Anticoagulation, mortality, bleeding and pathology among patients hospitalized with COVID-19: a single health system study. J Am Coll Cardiol 2020;76:1815–1826.

17. Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, Hohmann E, Chu HY, Luetkemeyer A, Kline S, Lopez de Castilla D, Finberg RW, Dieberk K, Tapson V, Hsieh L, Patterson TF, Paredes R, Sweeney DA, Short WR, Touloumi G, Ly C, Ohmagari N, Oh MD, Ruiz-Palacios GM, Benfield T, Fatkenheuer G, Kortepeter MG, Atmar RL, Creech CB, Lundgren J, Babiker AG, Pett S, Neaton JD, Burgess TH,Bonnett T, Green M, Makowski M, Osinusi A, Nayak S, Lane HC; ACTT-1 Study Group Members. Remdesivir for the treatment of Covid-19 - preliminary report. N Engl J Med 2020;382:2327–2336.

18. Green J, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A, Feldt T, Green G, Green ML, Lescurve F-X, Nicastri E, Oda R, Yo K, Quiros-Roldan E, Studemeister A, Redinski J, Ahmed S, Bennett J, Chelliah D, Chen D, Chihara D, Cohen SH, Cunningham J, D’Arminio Monforte A, Ismail S, Kato H, Lapadula G, L’Her E, Maeno T, Majumber M, Massari M, Mora-Rillo M, Mutoh Y, Nogues E, Osinusi AO, DeZure A, Zhao Y, Zhong L, Chokkalingam A, Elboudwarej E, Telep L, Timbs L, Henne I, Sellers S, Caio H, Tan SK, Winterbourne L, Desai P, Mera R, Gaggar A, Myers RP, Brainard DM, Chils R, Flanigan T. Compassionate use of remdesivir for patients with severe Covid-19. N Engl J Med 2020;382:2327–2336.

19. Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, Fu S, Gao L, Cheng Z, Lu Q, Hu Y, Luo G, Wang K, Lu Y, Li H, Wang S, Ruan S, Yang C, Mei C, Wang Y, Ding D, Wu F, Tang X, Ye X, Ye Y, Liu B, Yang J, Yin W, Wang A, Fan G, Zhou F, Liu Z, Gu X, Xu J, Shang L, Zhang Y, Cao L, Guo T, Wan Y, Qin H, Jiang Y, Jaki T, Hayden FG, Horby PW, Cao B, Wang C. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet 2020;395:1569-1578.

20. Group RC, Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, Staplin N, Brightling C, Ustianowski A, Elmahi E, Prudon B, Green C, Felton T, Chadwick D, Rege K, Fegan C, Chappell LC, Faust SN, Jaki T, Jeffery K, Montgomery A, Rowan K, Kuszczak E, Baillie JK, Haynes R, Landray MJ. Dexamethasone in hospitalized patients with Covid-19 - preliminary report. N Engl J Med 2020;doi: 10.1056/NEJMoa2021436.

21. Shen C, Wang Z, Zhao F, Yang Y, Li J, Yuan J, Wang F, Li D, Yang M, Xing L, Wei J, Xiao H, Yang Y, Qu J, Qiu J, Li L, Xu Z, Peng L, Li Y, Zheng H, Chen F, Huang K, Jiang Y, Liu D, Zhang Z, Liu Y, Liu L. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. JAMA 2020;323:1582.

22. Pesavento R, Ceccato D, Pasquetto G, Monticelli J, Leone L, Frigo A, Gorgi D, Postal A, Marchese GM, Cipriani A, Saller A, Sarais C, Crivellier P, Gemelli M, Capone F, Fioretto P, Pagano C, Rossato M, Avogaro A, Simioni F, Prandoni P, Vector R. The hazard of (sub)therapeutic doses of anticoagulants in non-critically ill patients with Covid-19: the Padua province experience. J Thromb Haemost 2020;18:2629-2635.